Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates
Authors
Jiesong Wang (ORCID: https://orcid.org/0000-0001-6846-0079)
Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates
Jiesong Wang, Huilai Zhang, Ganggang Wang, Feng Zhu et al.
Journal
Blood
Topics
Lymphoma Diagnosis and Treatment
article
Frontline brentuximab vedotin and PD-1 inhibitors in elderly Chinese Hodgkin lymphoma: Real-world survival benefits validated by geriatric and biomarker correlates
Jiesong Wang, Huilai Zhang, Ganggang Wang, Feng Zhu, Yan Jiang, Ji Ma, Dong Eun Song, Ou Bai, Shaozhen Chen, Chen Huang, Shu Zhao, Qingyuan Zhang, Junqing Xu, Zhao Peiqi, Yajun Li, Huixia Geng, Wei Guo, Min Bai, Jianxia He, Liping Su, Shu-Kai Qiao, Hui Zhou
article en
Abstract
No abstract available for this paper.
Publication Tag
BloodVol. 146(Supplement 1)
Institutions
Hebei Medical University (CN), Fujian Medical University (CN), Central South University (CN), Harbin Medical University (CN), Shanxi Medical University (CN), Xuzhou Medical College (CN), Jilin University (CN), Tianjin Medical University Cancer Institute and Hospital (CN), Yuhuangding Hospital (CN), Second Hospital of Hebei Medical University (CN), Shanxi Provincial Cancer Hospital (CN), Third Affiliated Hospital of Harbin Medical University (CN), Shanxi Province Hospital of Traditional Chinese Medicine (CN), Fourth Hospital of Hebei Medical University (CN), Affiliated Hospital of Xuzhou Medical College (CN), Hunan Cancer Hospital (CN), First Hospital of Jilin University (CN), Cancer Hospital of Chinese Academy of Medical Sciences (CN), Shanxi Academy of Medical Sciences (CN), Fourth People's Hospital of Taiyuan (CN), Shanxi Provincial People’s Hospital (CN), Shandong First Medical University (CN)